α‐synuclein Pathology and Treatment in the Enteric Nervous System | Chapter 10 | Research Aspects in Biological Science Vol. 9

 Neurocognitive Disorder with Lewy Bodies (NCDLB) and Parkinson's Disease patients frequently have synuclein (Lewy Body) pathology in their enteric nerve systems (ENS) (PD). Constipation, obstipation, and bowel impaction are examples of bowel immotility symptoms that can result from Lewy body disease in the ENS. It is discussed how synuclein (Lewy Body) disorder affects intestinal function specifically. These symptoms severely lower the patient's quality of life, which is difficult for both the patient and the caregivers. In theory, intestinal immobility in people with Lewy bodies can be considerably reduced or relieved with pharmacological treatment utilising acetylcholinesterase inhibitors (AChEIs). The justification for using the cholinergic agonist Donepezil to treat synuclein bowel dysfunction is discussed, along with a breakdown of how it works. The idea that AChEIs can lessen intestinal immotility brought on by Lewy bodies was investigated in longitudinal case studies. Donepezil showed effectiveness for reducing gastrointestinal dysfunction in Lewy body patients during a five-year period.

Author(s) Details:

Charles M. Lepkowsky,
Independent Practice, 1143 Deer Trail Lane, Solvang, CA 93463, United States.

Please see the link here: https://stm.bookpi.org/RABS-V9/article/view/8353

Donepezil and α-synuclein Constipation: A Longitudinal Study | Chapter 02 | New Horizons in Medicine and Medical Research Vol. 7

 In a case study, four patients with -synuclein or Lewy body disorders were diagnosed at various stages of their illness. In persons with Parkinson's disease (PD) and Neurocognitive Disorder with Lewy Bodies, the acetylcholinesterase inhibitor (AChEI) Donepezil was used to treat symptoms of constipation, obstipation, and impaction (NCDLB). Obstipation is characterised as severe constipation with bowel motions occurring only once or twice a week. Donepezil was connected to a significant reduction in symptom severity in all four individuals, which was sustained at six, twelve, eighteen, thirty-six, and forty-eight month intervals with no apparent loss in bowel motility or the introduction of new symptoms. According to the findings, the AChEI Donepezil can assist people with -synuclein disorders reduce their constipation, obstipation, and impaction symptoms over time.

Author(S) Details

Charles M. Lepkowsky
Independent Practice, 1143 Deer Trail Lane, Solvang, CA 93463-9519, United States.

View Book:- https://stm.bookpi.org/NHMMR-V7/article/view/6660